Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epicutaneous Allergen Immunotherapy for Grass Pollen Allergic Rhinoconjunctivitis
NCT00777374Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Oct 2008
- Primary completion
- Nov 2010
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Timothy grass pollen allergen extract in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by University of Zurich. Primary endpoint: Combined Symptom Medication Score. Started Oct 2008; status: completed.
02
Drugs
Timothy grass pollen allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00777374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777374.